Atkin-Jones Tariq, Ali Mohamed, Eze-Onuorah Akudo C J, Ifeanacho Ezinne, Khosravirad Azin, Madden Kim, Sadeghirad Behnam, Mbuagbaw Lawrence
Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
Pilot Feasibility Stud. 2025 May 19;11(1):70. doi: 10.1186/s40814-025-01655-z.
Pilot and feasibility studies are effective tools for assessing the feasibility of performing larger-scale studies. These are particularly useful in anesthesiology, where the research overlaps with several other medical and surgical fields. The objective of this meta-epidemiological study is to assess the design and methodology of pilot and feasibility randomized controlled trials (RCTs) in anesthesiology.
We searched for pilot and feasibility RCTs in anesthesiology indexed in PubMed during a 5-year span between January 1, 2018, and December 31, 2022. We extracted bibliographic information, field of study, type of intervention, trial duration, trial design, use of qualitative data, use of progression criteria, whether the primary objective and primary outcome were related to feasibility, reported feasibility outcomes, and sample size justification. We conducted logistic regression to determine the factors associated with using progression criteria, having primary feasibility outcomes, and using feasibility outcomes to justify the sample size. We controlled for publication year, journal impact factor, source of funding, intervention type, and region.
Our search retrieved 3015 trials, of which 248 were ultimately included and analyzed. Less than a third of studies stated feasibility as the primary objective (n = 77, 31.0%). Feasibility was a primary outcome in 46 (18.6%) studies, progression criteria were used in 27 (10.9%) studies, a sample size justification was listed in 134 (54.0%) studies, and 24 (9.7%) studies used qualitative data. We did not find any statistically significant association between progression criteria and any of the selected variables. Recently published trials had higher odds of having primary feasibility outcomes (odds ratio [OR] 1.39; 95% CI 1.06-1.83). Studies of pharmacological interventions had lower odds primary feasibility outcomes (OR 0.41; 95% CI 0.19-0.90). Recent studies also had higher odds of having a sample size justification based on a feasibility outcome rather than a clinical outcome or similar studies (OR 1.51; 95% CI 1.06-2.15).
More recently published pilot RCTs were significantly associated with having a primary feasibility outcome and determining sample size based on feasibility, while pharmacological studies were significantly associated with less reporting of primary feasibility outcomes. Future research addressing the factors limiting adherence to current guidelines is warranted.
预试验和可行性研究是评估开展大规模研究可行性的有效工具。这些研究在麻醉学中尤为有用,因为该领域的研究与其他多个医学和外科领域存在重叠。这项元流行病学研究的目的是评估麻醉学中预试验和可行性随机对照试验(RCT)的设计和方法。
我们检索了2018年1月1日至2022年12月31日这5年间在PubMed上索引的麻醉学预试验和可行性RCT。我们提取了书目信息、研究领域、干预类型、试验持续时间、试验设计、定性数据的使用、进展标准的使用、主要目标和主要结局是否与可行性相关、报告的可行性结局以及样本量合理性说明。我们进行了逻辑回归分析,以确定与使用进展标准、有主要可行性结局以及使用可行性结局来证明样本量合理性相关的因素。我们对发表年份、期刊影响因子、资金来源、干预类型和地区进行了控制。
我们的检索共找到3015项试验,其中最终纳入并分析了248项。不到三分之一的研究将可行性作为主要目标(n = 77,31.0%)。46项(18.6%)研究将可行性作为主要结局,27项(10.9%)研究使用了进展标准,134项(54.0%)研究列出了样本量合理性说明,24项(9.7%)研究使用了定性数据。我们未发现进展标准与任何选定变量之间存在任何统计学上的显著关联。近期发表的试验有主要可行性结局的几率更高(优势比[OR] 1.39;95%置信区间1.06 - 1.83)。药物干预研究有主要可行性结局的几率较低(OR 0.41;95%置信区间0.19 - 0.90)。近期研究基于可行性结局而非临床结局或类似研究来证明样本量合理性的几率也更高(OR 1.51;95%置信区间1.06 - 2.15)。
近期发表的预试验RCT与有主要可行性结局以及基于可行性确定样本量显著相关,而药物研究与主要可行性结局报告较少显著相关。有必要开展未来研究以探讨限制遵守当前指南的因素。